At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 6,228 enrolled
Drug / intervention
Salmeterol 50mcg/ Fluticasone Propionate 500mcgdrug
Likely dose
Salmeterol 50mcg/ Fluticasone Propionate 500mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment
In Brief
A Phase 3 clinical trial evaluating Salmeterol 50mcg/ Fluticasone Propionate 500mcg for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 6,228 participants across 459 sites in 44 countries.
Detailed Summary
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
Countries, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Pakistan, Philippines, Poland, Puerto Rico, Romania, Russia, Singapore, Slovakia, South Africa, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2000
Primary CompletionNov 2005
First PostedDec 2005
TodayJul 2026
First PostedDec 22, 2005
Enrollment StartSep 1, 2000
Primary CompletionNov 1, 2005
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 20.5 years ago
Interventions
Salmeterol 50mcg/ Fluticasone Propionate 500mcgdrug